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Abstract
Gram-negative bacteria are responsible for approximately one-third of the clinical cases of bovine mastitis and can elicit a
life-threatening, systemic inflammatory response. Lipopolysaccharide (LPS) is a membrane component of Gram-negative
bacteria and is largely responsible for evoking the inflammatory response. Antibiotic and anti-inflammatory therapy for treating
Gram-negative infections remains suboptimal. Bactericidal/permeability-increasing protein (BPI) is a neutrophil-derived
protein with antimicrobial and LPS-neutralizing properties. Select peptide derivatives of BPI are reported to retain these
properties. The objective of this study was to evaluate the antimicrobial activity of a human BPI-derived synthetic peptide
against clinical bovine mastitis isolates of Gram-negative bacteria. A hybrid peptide was synthesized corresponding to two
regions of human BPI (amino acids 90–99 and 148–161), the former of which has bactericidal activity and the latter of which has
LPS-neutralizing activity. The minimum inhibitory (MIC) and bactericidal (MBC) concentrations of this peptide against various
genera of bacteria were determined using a broth microdilution assay. The MIC’s were determined to be: 16–64 mg/ml against
Escherichia coli; 32–128 mg/ml against Klebsiella pneumoniae and Enterobacter spp.; and 64–256 mg/ml against Pseudomonas
aeruginosa. The MBC’s were equivalent to or 1-fold greater than corresponding MIC’s. The peptide had no growth inhibitory
effect on Serratia marcescens. The antimicrobial activity of the peptide was retained in the presence of serum, but severely
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impaired in milk. Further functional evaluation of the peptide demonstrated its ability to completely neutralize LPS. Together,
these data support additional investigations into the therapeutic application of BPI to the treatment of Gram-negative infections
in cattle.
Published by Elsevier B.V.
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1. Introduction
Approximately 20–30% of all clinical cases of
bovine mastitis are caused by Gram-negative bacteria,
and it is estimated that 10–30% of these clinical cases
develop into life-threatening, peracute mastitis (Ers-
kine et al., 1991; Ziv, 1992). The deleterious outcome
associated with severe Gram-negative intramammary
infections is due, in part, to the systemic inflammatory
response elicited by lipopolysaccharide (LPS), a
component of the outer bacterial membrane. Current
antibiotic therapy for the treatment of these infections
remains suboptimal, as do therapeutic options for
counteracting the excessive inflammatory response
elicited by LPS.
Bactericidal/permeability-increasing protein (BPI)
is a neutrophil-derived, cationic protein that possesses
bactericidal and LPS-binding activity (Elsbach, 1998).
There is 63% amino acid homology between the
human, rabbit, and bovine orthologs (Leong and
Camerato, 1990; Beamer et al., 1998), however, little
is known about the activity of bovine BPI. Recombi-
nant human BPI has been shown to have therapeutic
efficacy for the treatment of Gram-negative infections
(Kelly et al., 1993; Rogy et al., 1994; Levin et al.,
2000). The amino-terminal half of human BPI
(Gazzano-Santoro et al., 1992), as well as synthetic
peptides corresponding to amino acid sequences 65–
99 and 142–169, retain antibacterial and LPS-
neutralizing properties (Gray and Haseman, 1994;
Little et al., 1994; Little, 2002; Jiang et al., 2004).
The objective of the current study was to evaluate a
peptide with a sequence corresponding to two regions
within human BPI for its growth inhibitory activity
towards various bacteria that induce clinical bovine
mastitis. To our knowledge, this is the first study to
assess the activity of this peptide against clinical
mastitis bacterial isolates and to evaluate its function
in the physiologically relevant fluids of bovine sera
and milk.
2. Materials and methods
2.1. BPI-derived peptide (BPIpep)
A peptide [(KWKAQKRFLKKSKVGWLIQ-
LFHKK) (MW: 3027 g/mol)] corresponding to two
discontinuous regions of sequence within the mature
form of human BPI [amino acids 90–99 (underlined)
and 148–161] was commercially synthesized (Gen-
emed Synthesis, Inc., South San Francisco, CA).
Control peptides [(MCHWAGGASNTGDARGDV-
FGKQAG) (MW: 2394 g/mol)]; [(KAKAQKRFL-
KKSKVGALIQAFHKK) (MW: 2755 g/mol)]; and
[(KSKVGWLIQLFHKKKWKAQKRFLK) (MW:
3027 g/mol)] were synthesized by the same company.
High-performance liquid chromatography (HPLC)
andmass spectroscopy (MS) analysis were performed
by the commercial supplier to evaluate peptide purity
and confirm sequence identity (data not shown). The
purities of the peptides ranged between 95 and 98%.
The peptides were reconstituted in citrate-buffered
saline [CBS; 20 mM sodium citrate, 150 mM sodium
chloride, 0.1% pluronic F-68, and 0.002% polysor-
bate 80, pH 5.0 (SigmaChemical Co., St. Louis,MO)]
up to a final maximal concentration of 10 mg/ml,
aliquotted, and stored at 20 8C. CBS has been used
by others to reconstitute BPI and its derivatives (Lin
et al., 1996; Abrahamson et al., 1997; Beamer, 2002),
and the inclusion of pluronic F-68 and polysorbate 80
surfactants in CBS has been reported to improve
peptide stability and enhance resistance to aggrega-
tion, particle formation and precipitation (McGregor
et al., 1996). For those peptides that contained
aromatic amino acids, solubility in CBS was
confirmed by measuring the absorbance of the
dissolved peptides at 280 nm on a Beckman DU1
530 spectrophotometer (Beckman Coulter, Inc.,
Fullerton, CA). All aliquots of the reconstituted
peptides were thawed only once and diluted imme-
diately prior to use.
A. Chockalingam et al. / Veterinary Microbiology 125 (2007) 80–90 81
2.2. Bacterial strains
Isolates of Escherichia coli, Klebsiella pneumonia,
Serratia marcescens, Pseudomonas aeruginosa,
Enterobacter cloacae, and Enterobacter aerogenes,
were used to assess the bactericidal activity of
peptides in a broth microdilution assay. All isolates
were obtained from clinical cases of bovine mastitis
and held in repositories at Cornell University (gift of
Dr. Y.H. Schukken; Quality Milk Production Services
Program, Cornell University, Ithaca, NY) or the
USDA Beltsville Agricultural Research Center. E. coli
strain P4 (gift of Dr. A.J. Bramley; Institute for Animal
Health, Compton Laboratory, Newbury, England),
which was also originally isolated from a clinical case
of mastitis (Bramley, 1976), was used to assess the
bactericidal activity of BPIpep in both the broth
microdilution assay and in biological fluids. Reference
strains of E. coli (ATCC 25922) and Staphylococcus
aureus (ATCC 29213) were obtained from a com-
mercial source [American Type Culture Collection
(ATCC), Manassas, VA]. To obtain fresh inoculums
for evaluation, a sterile loop of each bacterial glycerol
stock was streaked on a blood agar plate. After
overnight incubation at 35 8C, a single uniform colony
was picked, streaked on a new blood agar plate, and
incubated overnight at 35 8C.
2.3. Broth microdilution assay for antimicrobial
susceptibility
To evaluate the antimicrobial activity of BPIpep, the
minimum inhibitory (MIC) and minimum bactericidal
(MBC) concentrations of the peptide were determined
using a standardized broth microdilution assay. In
addition to the mastitis isolates, E. coli (ATCC 25922)
and S. aureus (ATCC 29213) reference strains were
evaluated. The MIC and MBC values of tetracycline
(MW: 480.90 g/mol) (Sigma Chemical Co.) for the
various bacteria were determined as well. The assays
were performed in accordance with Clinical and
Laboratory Standards Institute (CLSI) [formerly
National Committee for Clinical Laboratory Stan-
dards (NCCLS)] guidelines (NCCLS, 1999, 2002).
First, a single colony of each fresh bacterial inoculum
was diluted in cation-adjusted Mueller-Hinton broth
(BD Biosciences, Franklin Lakes, NJ) and the
suspension adjusted to achieve a transmittance
equivalent to a 0.5 McFarland standard (108 CFU/
ml) using a colorimeter. The bacterial suspension was
then diluted 100-fold in cation-adjusted Mueller-
Hinton broth to reach a final inoculum concentration
of 106 CFU/ml. Fifty microliters of the inoculum were
added to individual wells within a 96-well round
bottom plate containing 50 ml of either broth alone, or
broth containing serially diluted peptide or tetracy-
cline. A negative control column was included in the
plate that included 100 ml of broth alone. The plates
were incubated for 18 h at 35 8C with ambient air
circulation and without shaking. The wells were
subsequently inspected for cloudiness and pellet
formation using a magnifying glass plate reader
(Dynatech Laboratories, Inc., Alexandria, VA). The
lowest concentration at which no pellet or cloudiness
was apparent in a givenwell was identified as theMIC.
The MBC values were determined by plating 10 ml
aliquots from the 96-well plates used to determine
MIC values onto blood agar plates. The plates were
incubated overnight at 35 8C and colonies subse-
quently enumerated. The MBC values were deter-
mined as the lowest concentration at which99.9% of
inoculated bacteria were killed.
2.4. Serum and whey preparation
Milk and blood samples were aseptically collected
from eight clinically healthy, primiparous Holstein
cows in mid-lactation with milk somatic cell counts of
<150,000 cells/ml. All cows were determined to be
free of intramammary pathogens by the absence of
bacterial growth on blood agar plates spread with milk
samples aseptically collected from each animal on 3
different days. For the preparation of whey, milk
samples were centrifuged at 44,000  g at 4 8C for
30 min, and the fat layer removed with a spatula. The
skim milk was transferred into another sterile tube,
centrifuged for an additional 30 min, and the
translucent supernatant collected. Milk and whey
samples were pasteurized by heating at 63 8C for
30 min. For the preparation of serum, blood was
collected from the coccygeal vein into vacutainer
tubes containing gel and clot activator (BD Bios-
ciences). The tubes were inverted 5, the blood
allowed to clot for 30 min, and the tubes centrifuged at
1500  g for 15 min. The clear serum supernatants
were aseptically transferred into sterile tubes and
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heat-inactivated by incubation at 56 8C for 30 min. An
aliquot of each sample was plated on blood agar plates
and samples that were free of detectable bacterial
growth were stored at 20 8C.
2.5. Assay of antimicrobial activity in serum, milk,
or whey
Overnight bacterial cultures of E. coli strain P4
grown in trypticase soy broth were diluted 1:1000 in
brain heart infusion broth and incubated at 37 8C for
2 h while shaking at 225 rpm. The log-phase bacteria
were diluted 1:10 in brain heart infusion broth to
obtain a final concentration of 1  106 CFU/ml. The
bacterial inoculum (0.01 ml) was added to a 1.5 ml
sterile microcentrifuge tube containing 0.04 ml of
serum, milk, or whey. A 0.05 ml aliquot of either
peptide or CBS alone was added to each tube. The
samples were then shaken at 100 rpm for 6 h at 37 8C
after which they were serially diluted in sterile
phosphate-buffered saline and plated on MacConkey
agar plates (BD Biosciences). The plates were
incubated overnight at 37 8C and the colonies
enumerated. For assays examining the effect of
ethylenediaminetetraacetic acid (EDTA; MW:
372.24 g/mol) (Quality Biological, Inc., Gaithersburg,
MD) or cations on BPIpep antimicrobial activity in
milk or whey, the same procedure was followed as
above except that 0.025 ml aliquots of varying
concentrations EDTA or cations [CaCl2 (MW:
110.98 g/mol) or MgCl2 (MW: 95.21 g/mol); Sigma
Chemical Co.] were added to milk or whey,
respectively, followed by the addition of 0.01 ml
inoculums of bacteria and 0.025 ml aliquots of either
BPIpep or CBS.
2.6. Assay for neutralization of LPS
The ability of BPIpep or control peptides to
neutralize LPS was determined using a commercially
available Limulus amebocyte lysate (LAL) assay
(Cambrex BioScience Walkersville, Inc., Walkers-
ville, MD). Polymyxin B (MW: 1385.61 g/mol)
(Sigma Chemical Co.), which has been demonstrated
to bind and neutralize LPS (Cooperstock, 1974;
Bannerman et al., 1998), was evaluated in parallel.
Increasing concentrations of peptides or polymyxin B
were incubated with 1 ng of highly purified LPS,
derived from E. coli 0111:B4 (Sigma Chemical Co.),
in a 500 ml reaction volume of endotoxin-free water
for 30 min at 37 8C while shaking at 100 rpm.
Following incubation, the amount of free LPS was
determined in each sample according to the manu-
facturer’s instructions. Briefly, 50 ml of the above
mixture were placed into individual wells of a 96-well
microtiter plate and the reaction initiated by the
addition of an equal volume of amebocyte lysate.
Following incubation at 37 8C for 10 min, 100 ml of
chromogenic substrate was added and the plate
incubated for 5–10 min at 37 8C. The reaction was
stopped by the addition of 50 ml of glacial acetic acid
and the absorbance measured at a wavelength of
405 nm on a microplate reader (Biotec Instruments,
Inc., Winooski, VT). The amount of non-bound LPS
was extrapolated from a standard curve and the
percent inhibition calculated according to the follow-
ing formula:
½ðamount of free LPS in control samplesÞ
 ðamount of free LPS in test samplesÞ  100
amount of free LPS in control samples
2.7. Statistical methods
For studies investigating the effect of EDTA or
cations on BPI antimicrobial activity, a one-way
analysis of variance was used to compare the mean
responses between experimental groups. The Dunnett
post hoc comparison test was used to compare values
among experimental conditions to designated control
groups. Statistical analyses were performed using
GraphPad Prism version 4.03 for Windows (GraphPad
Software, Inc., San Diego, CA). A P-value of <0.05
was considered significant.
3. Results and discussion
3.1. BPIpep synthesis
Peptide mapping has identified regions within
amino acids 65–99 and 142–169 of human BPI as
conferring bactericidal and LPS-neutralizing activity,
respectively (Little et al., 1994). Within amino acids
65–99, bactericidal activity has been shown to be
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conferred by a subset region within amino acids 85–99
and a synthetic peptide corresponding to amino acids
90–99 of human BPI has been demonstrated to possess
bactericidal activity (Gray and Haseman, 1994; Little
et al., 1994). Several regions within BPI confer LPS-
binding capability and a peptide corresponding to
amino acids 148–161 has been reported to neutralize
LPS (Little et al., 1994; Jiang et al., 2004). Peptides
that contain fused sequences of amino acid regions
corresponding to different functional domains within
BPI show both bactericidal and LPS-neutralizing
activity (Gray and Haseman, 1994). Thus, a peptide
corresponding to human BPI amino acids 90–99 and
148–161 was synthesized to evaluate whether the
fusion of sequences of amino acid regions from two
functional domains of BPI retained bifunctionality and
exerted bactericidal activity against various bacterial
species isolated from clinical cases of bovine mastitis.
3.2. Susceptibility of clinical mastitis bacterial
isolates to the bacteriostatic and bactericidal
effects of BPIpep
The broth microdilution susceptibility assay was
used to assess the spectrum of activity of BPIpep
against various Gram-negative bacteria isolated from
clinical cases of mastitis (Table 1). The range of MIC
and MBC values from six assays are shown. With the
exception of S. marcescens, all species were suscep-
tible to the bacteriostatic and bactericidal effects of
BPIpep. The peptide’s MIC values were64 mg/ml for
all E. coli isolates, and 128 mg/ml for five of the six
isolates of P. aeruginosa and all isolates of K.
pneumoniae and Enterobacter. At concentrations up to
512 mg/ml, BPIpep had no demonstrable growth
inhibitory effect on any of the S. marcescens isolates
tested. Because others have reported that S. marces-
cens is resistant to the bactericidal effects of full-
length human and rabbit BPI (Beckerdite et al., 1974;
Levy et al., 2000), it is not surprising that this
bacterium is resistant to a peptide derived from the
human BPI protein.
Interestingly, the reference strain of S. aureus
exhibited sensitivity to the bacteriostatic and bacter-
icidal effects of BPIpep. Although S. aureus is
reportedly resistant to the bactericidal activity of
the full-length BPI protein, peptides containing
sequence corresponding to amino acids 90–99 of this
protein have been demonstrated to be bactericidal
against S. aureus (Gray and Haseman, 1994). Thus,
the sensitivity of S. aureus to BPIpep reported here is
consistent with the findings of a previous study.
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Table 1
Antimicrobial activity of a human BPI-derived peptide (BPIpep)
against clinical mastitis isolates of Gram-negative bacteria
BPIpep Tetracycline
MIC MBC MIC MBC
Enterobacter aerogenes
Isolate #1 32–64 32–128 >128 >128
Enterobacter cloacae
Isolate #1 64 64 >128 >128
Isolate #2 32–64 32–64 2–4 >128
Isolate #3 64–128 64–128 128 128
Isolate #4 32–64 32–128 4–16 >128
Escherichia coli
Isolate #1 16 32 2 64–128
Isolate #2 16–32 16–32 2 >128
Isolate #3 32 32–64 2 >128
Isolate #4 32–64 32–64 2 >128
Isolate #5 32–64 32–128 2 64–128
Strain P4 32–64 64–128 1–2 >128
ATCC 25922 32–64 32–64 0.5–1 32–128
Klebsiella pneumoniae
Isolate #1 32–64 32–64 64–128 128
Isolate #2 32–64 32–64 128 128
Isolate #3 64–128 64–128 2 128
Isolate #4 64–128 64–128 64–128 128
Isolate #5 32–64 32–64 2 128
Isolate #6 32–64 32–64 1–16 128
Pseudomonas aeruginosa
Isolate #1 64–128 64–128 16 >128
Isolate #2 64–128 64–128 8–16 >128
Isolate #3 64–128 64–128 64 128
Isolate #4 64–128 64–256 16–32 >128
Isolate #5 128–256 128–256 32 >128
Isolate #6 64–128 64–128 16–32 >128
Serratia marcescens
Isolate #1 >512 >512 32–64 >128
Isolate #2 >512 >512 64 >128
Isolate #3 >512 >512 64 >128
Isolate #4 >512 >512 64 >128
Isolate #5 >512 >512 64 >128
Isolate #6 >512 >512 64 >128
Staphylococcus aureus
ATCC 29213 128–256 128–256 <0.25–1 128 to >128
Minimum inhibitory (MIC) and bactericidal concentrations (MBC)
are reported as mg/ml. The range of values from six broth micro-
dilution assays evaluating peptide antimicrobial activity is shown.
The MBC values of BPIpep were equivalent to or
1-fold higher than the range of MIC values for each
susceptible strain (Table 1). For comparison, each
bacterial isolate was also evaluated for its suscept-
ibility to the bacteriostatic antibiotic, tetracycline.
Within the concentration range tested, tetracycline
inhibited the growth of almost all clinical mastitis
isolates. Tetracycline MIC values for the two
reference strains, E. coli ATCC 25922 and S. aureus
ATCC 29213, were within the established quality
control ranges of 0.5–2 and 0.12–1 mg/ml, respec-
tively (NCCLS, 1999). With the exception of two
isolates of Enterobacter spp. and one isolate of K.
pneumoniae, the MIC values of tetracycline were
lower than that of BPIpep. The MBC values of
tetracycline were generally higher than those of
BPIpep. Thus, in contrast to the approximate 1:1–2:1
MBC:MIC ratios of BPIpep, the ratio of tetracycline
MBC values relative to those of its MIC were higher.
These data are consistent with the bacteriostatic nature
of tetracycline and the bactericidal nature of BPI.
3.3. Effect of amino acid substitutions and
changes in sequence order on the bacteriostatic
and bactericidal effects of BPIpep
To determine whether the functionality of this 24-
mer peptide was dependent upon specific amino acid
composition or order, the antimicrobial activity of
BPIpep and three control peptides against the E. coli P4
strain were evaluated in parallel in the broth
microdilution susceptibility assay (Table 2). To rule
out that any random 24-mer peptide synthesized at
comparable purity to that of BPIpep could exert
antimicrobial activity, a control peptide (Ctrlpep1) was
designed with an amino acid composition devoid of
any sequence identity to BPIpep. In contrast to BPIpep,
which displayed MIC’s and MBC’s as low as 16 and
64 mg/ml, respectively, Ctrlpep1 did not demonstrate
any growth inhibitory or bactericidal activity at
concentrations 1024 mg/ml.
BPIpep, similar to the whole BPI protein and other
peptides with activity against Gram-negative bacteria,
contains a high proportion of basic amino acids
(Blondelle and Houghten, 1992; Nicolas and Mor,
1995; Pazgier et al., 2007). To determine whether the
highly basic composition of BPIpep was solely
responsible for its activity, a second control peptide
(Ctrlpep2) was synthesized to contain alanine amino
acids substituted for two corresponding tryptophans
and one corresponding leucine within BPIpep.
Although this peptide contained the same proportion
of basic and non-polar amino acids as BPIpep, Ctrlpep2
did not demonstrate any antimicrobial activity at
concentrations <1024 mg/ml (Table 2). Thus, the
antimicrobial activity of BPIpep cannot be solely
ascribed to its high content of basic amino acids.
Finally, to determine whether the specific order of
amino acids within BPIpep influenced activity, a third
control peptide (Ctrlpep3) was designed so that the
stretch of amino acids corresponding to amino acids
90–99 within BPI protein (i.e., the first 10 amino acids
in BPIpep) were placed after the amino acids
corresponding to amino acids 148–161 within BPI
(i.e., the last 14 amino acids in BPIpep). Reversing the
order of these two stretches of amino acids decreased
peptide activity, and corresponding MIC and MBC
values were approximately 3–7 and 1–3-fold higher,
respectively, than BPIpep. Together, these data estab-
lish that the order and composition of amino acids
within BPIpep specifically influence antimicrobial
activity of the peptide.
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Table 2
Antimicrobial activity of a human BPI-derived peptide and various control peptides against Escherichia coli strain P4
Peptide designation Modification Sequence MICa MBC
BPIpep – KWKAQKRFLKKSKVGWLIQLFHKK 16–32 64
Ctrlpep1 Unrelated sequence MCHWAGGASNTGDARGDVFGKQAG >1024 >1024
Ctrlpep2 Alanine substitutions
b KAKAQKRFLKKSKVGALIQAFHKK 1024 1024
Ctrlpep3 Reversed domains
c KSKVGWLIQLFHKKKWKAQKRFLK 128 128–256
a Minimum inhibitory (MIC) and bactericidal concentrations (MBC) are reported asmg/ml. The range of values from four broth microdilution
assays evaluating peptide antimicrobial activity is shown.
b Amino acids within BPIpep substituted with alanine are bolded and underlined.
c Reversal of the order of the two functional domains within BPIpep are indicated with different font styles.
3.4. Comparative bactericidal activity of BPIpep
in physiological fluids
To determine whether BPIpep retained bactericidal
activity in physiological fluids, the peptide was
incubated with E. coli strain P4 (1  105 CFU/ml)
in broth, serum or milk for 6 h (Table 3). This strain
was chosen for evaluation because of its origin from a
clinical case of mastitis and well-characterized
pathogenesis (Bramley, 1976; Anderson et al., 1977;
Bannerman et al., 2004). At concentrations 10 mg/
ml, BPIpep demonstrated bactericidal activity against
E. coli in both broth and serum. In milk, however, the
peptide demonstrated no bactericidal activity, even at
a concentration that was 100 the effective dose in
broth and serum. BPIpep did exert a bacteriostatic
effect in milk at a concentration of 1000 mg/ml and
inhibited bacterial growth by >99%.
To assess whether components in a particular
fraction of milk might be responsible for the inhibition
of BPIpep activity, the peptide was evaluated in whey,
which is the protein-rich liquid fraction of milk devoid
of cells, casein, and fat (Table 3). At 10 and 100 mg/
ml, respectively, the peptide exhibited complete
growth inhibitory and bactericidal activity against
E. coli.
3.5. Effect of EDTA on BPIpep activity in milk
Divalent cations are known to impair the activity of
and/or sensitivity to various antibiotics (Russell, 1967;
Miles and Maskell, 1986; Miles et al., 1986).
Magnesium and calcium, which are present at high
concentrations in milk, have been reported to inhibit
the activity of the full-length BPI protein (Weiss et al.,
1975, 1978). To determine whether high cation
concentrations contribute to the loss of BPIpep activity
in milk, increasing concentrations of the divalent
chelator EDTA were added to milk and BPIpep
antimicrobial activity assayed (Fig. 1). In the absence
of BPIpep, EDTA demonstrated no growth inhibitory
effect on E. coli at concentrations 8 mM. The
bacterial growth in milk during the 6 h incubation
period, from a starting inoculating concentration of
A. Chockalingam et al. / Veterinary Microbiology 125 (2007) 80–9086
Table 3
Antimicrobial activity of a human BPI-derived peptide (BPIpep) against Escherichia coli strain P4 in various biological fluids
BPIpep (mg/ml) Broth Serum Milk Whey
Mean S.E. n Mean S.E. n Mean S.E. n Mean S.E. n
0 8.90 0.02 5 8.20 0.05 8 8.96 0.08 8 8.81 0.08 8
0.01 8.85 0.03 5 8.21 0.04 8 N.D. – – N.D. – –
0.1 8.68 0.04 5 8.17 0.03 8 N.D. – – 8.71 0.21 8
1 3.56 0.97 5 7.90 0.14 8 N.D. – – 8.05 0.26 8
10 0 0 5 0 0 8 8.95 0.09 8 4.85 0.2 8
100 0 0 5 0 0 8 7.60 0.18 8 0 0 8
1000 N.D. – – N.D. – – 6.67 0.042 8 0 0 8
Mean (S.E.) log10 colony forming units are reported. n: number of replicates. N.D.: not determined
Fig. 1. Effect of EDTA on the bacteriostatic and bactericidal
activity of a human BPI-derived peptide (BPIpep) in milk. Various
concentrations of BPIpep and/or EDTAwere added to milk contain-
ing 1  105 CFU/ml of E. coli strain P4. The inoculated milk was
then incubated for 6 h at 37 8C, and subsequently serially diluted and
plated. On the following day, colonies were enumerated and the
mean (S.E.) log10 CFU/ml calculated (S.E. bars smaller than the
size of corresponding symbols are not shown). For each concentra-
tion of EDTA, the asterisk (*) denotes a significant difference
(P < 0.05) relative to inoculums grown in the same concentration
of EDTA in the absence of BPIpep (i.e., 0 mg/ml; solid line with
closed circles). For each concentration of BPIpep, the pound sign (#)
denotes a significant difference (P < 0.05) relative to inoculums
exposed to the same concentration of BPIpep in the absence of EDTA
(i.e., 0 mM).
1  105 CFU/ml to a final concentration of
8.14  108 CFU/ml, was completely inhibited in the
presence of 16 mM EDTA. Consistent with results
shown in Table 3, BPIpep at a concentration of
1000 mg/ml demonstrated growth inhibitory activity
in milk even in the absence of EDTA (i.e., 0 mM). In
the presence of 16 mM EDTA, all concentrations of
BPIpep demonstrated bactericidal activity in milk. At
the highest concentration of EDTA that did not exert a
bacteriostatic effect (i.e., 8 mM), all three concentra-
tions of BPIpep demonstrated growth inhibitory
activity and those 100 mg/ml inhibited >99% of
E. coli growth in milk. These findings suggest that
cations contribute to the impairment of BPIpep
antimicrobial activity in milk.
3.6. Effect of cations on BPIpep activity in whey
As shown in Table 3, BPIpep demonstrated
bactericidal activity in whey, but not in milk.
Approximately 25 and 65%, respectively, of the total
magnesium and calcium content of milk is associated
with casein (Fransson and Lonnerdal, 1983; Gau-
cheron, 2005; Neville, 2005). Whey, which is depleted
of casein, contains correspondingly reduced levels of
these cations. Thus, it could be hypothesized that
BPIpep retains its antimicrobial activity in whey due to
the lower concentrations of cations that are present in
whey. To determine whether increasing the cation
concentration in whey could impair BPIpep activity,
the antimicrobial effects of BPIpep against E. coli
strain P4 was assayed in whey spiked with increasing
concentrations of MgCl2 or CaCl2 (Fig. 2). Relative to
activity in normal (unspiked) whey, BPIpep demon-
strated reduced activity in whey spiked with 3 mM
Mg2+ or Ca2+. These data are consistent with those
reported in a previous study demonstrating inhibition
of the antimicrobial activity of the whole human BPI
protein in the presence of 2.5 mM Mg2+ or Ca2+
(Weiss et al., 1978). In the presence of 30 mM Ca2+,
BPIpep lost all growth inhibitory activity in whey
(Fig. 2B). Because the reported concentrations of
Mg2+ and Ca2+ in milk range from 4 to 6 and 26 to
32 mM (Gaucheron, 2005), respectively, these data
demonstrate that BPIpep loses its activity in whey
supplemented with concentrations of magnesium or
calcium approaching those in milk. This finding, in
combination with data demonstrating that chelation of
cations enhances BPIpep activity in milk, suggests that
the differential activity of BPIpep in whey and milk can
be attributed, in part, to differences in cation
concentrations.
In addition to the potential inhibitory roles of
divalent cations to inhibit BPIpep activity in milk, one
cannot exclude the possibility that other components
are capable of sequestering BPIpep and restricting it
from contacting the bacterial cell wall. Milk contains
an abundance of sialoglycoconjugates, including
sialic acid bound oligosaccharides and glycoproteins
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Fig. 2. Effect of cations on the bacteriostatic and bactericidal
activity of a human BPI-derived peptide (BPIpep) in whey. BPIpep
(800 mg/ml) or citrate-buffered saline (CBS) were added to whey
containing 1  105 CFU/ml of E. coli strain P4 and spiked with
varying concentrations of MgCl2 (A) or CaCl2 (B). The mixture was
incubated for 6 h at 37 8C, and subsequently serially diluted and
plated. On the following day, colonies were enumerated and the
mean (S.E.) log10 CFU/ml calculated (S.E. bars smaller than the
size of corresponding symbols are not shown). *Significantly
(P < 0.05) decreased relative to inoculums grown in CBS at the
same concentration of spiked cation. #Significantly (P < 0.05)
increased relative to inoculums exposed to BPIpep in the absence
of spiked cations (i.e., 0 mM).
(Mather and Keenan, 1975; Martin et al., 2001). Both
BPIpep and the mature, native form of BPI are basic
molecules with pI’s of 11.51 and 9.44, respectively;
therefore, ionic interactions between sialic acid and
these molecules are possible. Such interactions could
impair the therapeutic efficacy of recombinant BPI
and/or BPI-derived peptides in milk and may also
impede endogenous neutrophil-derived BPI from
exerting its bactericidal activity against intramam-
mary bacteria during mastitis.
3.7. LPS-neutralizing activity of BPIpep
To determine whether BPIpep could neutralize LPS
at concentrations commensurate with those that were
bactericidal, increasing concentrations of the peptide
were incubated with LPS (1 ng) and the resulting
mixture assayed in the LAL assay (Fig. 3). Three
control peptides and polymyxin B, the latter of which
is a potent neutralizer of LPS, were also evaluated. At
concentrations of 10 and 30 mg/ml, respectively,
BPIpep inhibited 27 and 90% of LPS bioactivity
(Fig. 3A). In the presence of 100 mg/ml of BPIpep, LPS
was completely neutralized. Ctrlpep1, which lacks any
sequence identity with BPIpep, demonstrated no LPS-
neutralizing activity even at 100 mg/ml. Ctrlpep2,
which contains alanine amino acids substituted for
two corresponding tryptophans and one corresponding
leucine within BPIpep, neutralized <50% of LPS
activity at the maximal concentration tested (i.e.,
100 mg/ml). At concentrations ranging from 1 to
30 mg/ml, Ctrlpep2 inhibited LPS bioactivity by15%.
This effect appeared to be non-specific as there was no
concentration-dependent change in Ctrlpep2 activity
within this concentration range. Ctrlpep3, whose
sequence corresponded to the last 14 amino acids
within BPIpep followed by the first 10 amino acids
within BPIpep, demonstrated reduced LPS-neutraliz-
ing activity compared with BPIpep. At 10 and 30 mg/
ml, Ctrlpep3 inhibited 1 and 33% of LPS bioactivity. At
100 mg/ml, Ctrlpep3 neutralized 87% of LPS activity.
Polymyxin B inhibited LPS activity in a dose-
dependent manner and neutralized >90% of LPS
bioactivity at concentrations 10 mg/ml. On a raw
mass/volume basis, a concentration of BPIpep 2
higher than that of polymyxin B was necessary to
achieve comparable neutralization. On a molar basis,
however, a BPIpep concentration (9.91 mM) only
0.37 higher than that of polymyxin B (7.22 mM)
was necessary to achieve 90% inhibition of LPS
bioactivity (Fig. 3B). The effective molar concentra-
tions at which polymyxin B, BPIpep, and Ctrlpep3 could
inhibit 50% of LPS bioactivity were 1.6, 5.8, and
17 mM, respectively. At the concentrations tested,
Ctrlpep1 and Ctrlpep2 were unable to inhibit 50% of
activity.
In terms of bifunctional capability to neutralize
LPS and kill bacteria, BPIpep exhibited both effects at
concentrations <100 mg/ml. This combined activity
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Fig. 3. LPS-neutralizing activity of a peptide derived from human
BPI (BPIpep). E. coli-derived LPS (1 ng) was incubated with various
concentrations of BPIpep, control peptides, or polymyxin B for
30 min. Following incubation, the amount of free LPS was deter-
mined with the Limulus amebocyte lysate assay and the mean
(S.E.) percent of bound (neutralized) LPS calculated (S.E. bars
smaller than the size of corresponding symbols are not shown).
Concentrations of tested agents (x-axis) are shown in mg/ml (A) and
mM (B) units on a log scale.
of the peptide indicates its potential for therapeutic
application to the treatment Gram-negative infections.
Currently approved antibiotics for systemic use only
target the pathogen and do not counteract the LPS
molecule, the latter of which is responsible for
evoking the excessive inflammatory response that
threatens the life of the animal. BPIpep, however, has
the ability to target both the pathogen and LPS.
The demonstrated bactericidal activity of BPIpep in
serum suggests that additional studies investigating its
therapeutic potential for the treatment of septicemia are
warranted. The impaired bactericidal activity of BPIpep
in milk may diminish interest in further evaluating its
therapeutic potential for the treatment of intramammary
infections. However, the cations that may be respon-
sible for the impairment of BPIpep activity in normal
milk are reported to decrease by>50% during mastitis
(Bogin and Ziv, 1973; El Zubeir et al., 2005). Thus,
changes in milk composition during the course of
mastitismay enable BPIpep to have a therapeutic benefit
in the treatment of this disease.
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